Zymeworks is a clinical-stage biotechnology company developing innovative therapeutics for patients with difficult-to-treat diseases, including cancer and autoimmune conditions.
Investigational medicines that have not been approved by a regulatory authority, such as the U.S. Food and Drug Administration, may or may not be safe and effective as treatment options. Clinical trials are carefully designed to evaluate the safety and efficacy of investigational medicines. Expanded Access (also known as compassionate use) refers to a pathway by which patients with serious or life-threatening diseases may be able to obtain access to an investigational medicine outside of a clinical trial.
At this stage in our clinical development, Zymeworks does not offer an Expanded Access Program for its investigational medicines. We encourage patients to discuss potential participation in clinical trials with their treating physician. Information about Zymeworks’ ongoing clinical trials, including eligibility criteria and locations, can be found at www.clinicaltrials.gov.
We recognize the significant unmet medical need faced by many patients and will continue to evaluate our policy as additional data become available from ongoing and future clinical trials.
For questions regarding Zymeworks’ Expanded Access Policy, please contact: medical@zymeworks.com.
